Search
Now showing items 21-30 of 39
Mefv Mutation Frequency And Effect On Disease Severity In Ankylosing Spondylitis
(Tubitak Scientific & Technical Research Council Turkey, 2014)
Background/aim: To define the frequency of familial Mediterranean fever gene (MEFV) mutations in ankylosing spondylitis (AS) and describe different clinical aspects of MEFV mutation carrier and noncarrier AS patients. ...
Report of the Grappa-Omeract Psoriatic Arthritis Working Group From The Grappa 2015 Annual Meeting
(J Rheumatol Publ Co, 2016)
The GRAPPA-OMERACT psoriatic arthritis (PsA) working group is in the process of updating the PsA core domain set to improve and standardize the measurement of PsA outcomes. Work streams comprise literature reviews of domains ...
Behçet Disease With Vascular Involvement
(2015)
Vascular involvement is one of the major causes of mortality and morbidity in Behçet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only ...
Monitoring Achilles Enthesitis In Ankylosing Spondylitis During Tnf-Alpha Antagonist Therapy: An Ultrasound Study
(Oxford Univ Press, 2010)
Objective. Enthesitis is considered as the primary anatomical lesion in ankylosing spondylitis (AS). Therapeutic effects of TNF-alpha antagonist treatments for enthesitis on imaging changes are still limited to case reports ...
Updating The Psoriatic Arthritis (Psa) Core Domain Set: A Report From The Psa Workshop At Omeract 2016
(J Rheumatol Publ Co, 2017)
Objective. To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and ...
International Patient and Physician Consensus on a Psoriatic Arthritis Core Outcome Set for Clinical Trials
(2017)
Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA) clinical trials that represent both patients' and physicians' priorities. Methods We conducted (1) a systematic literature ...
Starting Of Biological Disease Modifying Antirheumatic Drugs May Be Postponed In Rheumatoid Arthritis Patients With Multimorbidity
(2018)
The objective of this study was to assess the frequency of comorbidities and multimorbidities in rheumatoid arthritis (RA) patients under biologic therapy and their effects on biological disease modifying antirheumatic ...
Tuberculosis And Viral Hepatitis Infection In Eastern Europe, Asia, And Latin America: Impact Of Tumor Necrosis Factor-Α Inhibitors In Clinical Practice
(2018)
Tumor necrosis factor-α (TNF-α) inhibitors are increasingly becoming the standard of care for treating a number of inflammatory diseases. However, treatment with TNF-α inhibitors carries an inherent risk of compromising ...
Rituximab Therapy in Renal Amyloidosis Secondary To Rheumatoid Arthritis
(2018)
Secondary amyloid A (AA) amyloidosis is a late and serious complication of poorly controlled, chronic inflammatory diseases. Rheumatoid arthritis (RA) patients with poorly controlled, longstanding disease and those with ...
Defining Outcome Measures For Psoriatic Arthritis: A Report From The Grappa-Omeract Working Group
(J Rheumatol Publ Co, 2017)
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic ...